+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Age Related Macular Degeneration (AMD) Market Size, Share & Industry Trends Analysis Report By Drug Type (Aflibercept, Ranibizumab and Others), By Disease Type (Wet and Dry), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 126 Pages
  • July 2023
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5868789
The Europe Age Related Macular Degeneration (AMD) Market should witness market growth of 5.0% CAGR during the forecast period (2023-2030).

The macula, a region of the retina responsible for central vision, is impacted by age-related macular degeneration (AMD), a degenerative eye condition. As a person ages, the cells in the macula suffer damage and start to die, which results in vision loss. Wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD) are the main illness classifications. Wet AMD is less common and involves the development of abnormal blood vessels beneath the macula. In contrast, dry AMD is more prevalent and involves the creation of small, yellow deposits in the macula.

Treatment options for dry AMD include vitamin supplements and lifestyle modification to lower risk factors. To treat wet AMD, eye injections of drugs are used to prevent the development of abnormal blood vessels. This medicine, known as aberrant endothelial growth factor (anti-VEGF) therapy, stops the protein from promoting the development of abnormal blood vessels. The market is essential to solving the problem of visual loss that the senior population faces.

Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with at least one individual who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow because of the aging populations in these regional nations.

The Germany market dominated the Europe Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $842 million by 2030. The UK market is exhibiting a CAGR of 4.1% during (2023-2030). Additionally, The France market would experience a CAGR of 5.7% during (2023-2030).

Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.

Scope of the Study

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet
  • Dry

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • Biogen, Inc.
  • Bayer AG
  • Apellis Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Sanofi S.A.
  • Coherus Biosciences, Inc.
  • Bausch Health Companies, Inc.

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 Europe Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 Europe Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 Europe Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. Europe Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 Europe Aflibercept Market by Country
5.2 Europe Ranibizumab Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 Europe Wet Market by Country
6.2 Europe Dry Market by Country
Chapter 7. Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 Europe Hospital Pharmacy Market by Country
7.2 Europe Retail Pharmacy Market by Country
7.3 Europe Online Pharmacy Market by Country
Chapter 8. Europe Age Related Macular Degeneration (AMD) Market by Country
8.1 Germany Age Related Macular Degeneration (AMD) Market
8.1.1 Germany Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 Germany Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 UK Age Related Macular Degeneration (AMD) Market
8.2.1 UK Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 UK Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 France Age Related Macular Degeneration (AMD) Market
8.3.1 France Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 France Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 France Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 Russia Age Related Macular Degeneration (AMD) Market
8.4.1 Russia Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 Russia Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.5 Spain Age Related Macular Degeneration (AMD) Market
8.5.1 Spain Age Related Macular Degeneration (AMD) Market by Drug Type
8.5.2 Spain Age Related Macular Degeneration (AMD) Market by Disease Type
8.5.3 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.6 Italy Age Related Macular Degeneration (AMD) Market
8.6.1 Italy Age Related Macular Degeneration (AMD) Market by Drug Type
8.6.2 Italy Age Related Macular Degeneration (AMD) Market by Disease Type
8.6.3 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.7 Rest of Europe Age Related Macular Degeneration (AMD) Market
8.7.1 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type
8.7.2 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type
8.7.3 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.10. Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis

Companies Mentioned

  • Biogen, Inc.
  • Bayer AG
  • Apellis Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Sanofi S.A.
  • Coherus Biosciences, Inc.
  • Bausch Health Companies, Inc.

Methodology

Loading
LOADING...